Cinnarizine PCD Pharma Franchise Company
Cafoli Lifecare offers a Cinnarizine range of 5 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving ENT and general practice can secure district-wise monopoly franchise rights on this established anti-vertigo molecule.
What is Cinnarizine?
Cinnarizine is an antihistamine and calcium channel blocker with anti-vertigo and anti-motion-sickness activity. It suppresses vestibular stimulation and reduces labyrinthine excitability, easing giddiness and nausea of vestibular origin. Compound details are available on PubChem.
Therapeutic Applications
Cinnarizine is used for vertigo, Meniere disease, motion sickness, tinnitus and vestibular disorders, frequently in combination with dimenhydrinate for acute vertigo. Prescribers include ENT specialists, neurologists and general physicians.
Why Cinnarizine is a High-Potential Molecule for Distributors
Vertigo and giddiness are high-frequency complaints in both ENT and GP practice, and cinnarizine-based tablets are a long-standing first-line therapy. Because episodes recur, patients return for repeat courses, and the combination formats face limited competition, giving franchise partners a steady, defensible niche within a general or ENT-focused range.
Why Choose Cafoli Lifecare
Cafoli Lifecare is a WHO-GMP compliant, DCGI-approved PCD pharma company with 1000+ franchise partners across India. Partners receive district-wise monopoly rights, promotional inputs including visual aids, MR bags and product cards, and consistent stock availability backed by quality-tested manufacturing.
References
- PubChem: Cinnarizine
- PubMed: Cinnarizine in vertigo
Our formulations of Cinnarizine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: